Sanofi, a global pharmaceutical company and long-term partner of KBI, recently published their research work performed in collaboration with KBI in high impact journals.
Scientists from Sanofi global diabetes research and translational medicine team and KBI systematically studied the mechanism of action of dual agonists of GLP-1 /glucagon receptors on glucose, body weight and energy homeostasis using KBI’s diet-induced NHP model of metabolic syndrome. Both teams also worked together and revealed the pharmacological effect of Sanofi’s novel GLP-1/glucagon receptor co-agonists in body weight and glycemic control in obese and diabetic NHPs. The research work has been published in the recent issues of Diabetes, Obesity and Metabolism [20(8):1836-1851], and in Endocrinology [159(8):3105-3119, 2018].

“These two papers published by Sanofi in the prestigious journals further demonstrate the translational value of KBI’s unique monkey models with metabolic dysregulations”, said Zhiming Ding, KBI’s CSO.  “We are grateful to Sanofi who has selected KBI as the preclinical service provider, and KBI is proud of being the partner of a global leader in the field to pursue scientific excellence. KBI commits to providing translational NHP disease models and pharmacology solutions to accelerate our collaborator’s drug discovery and development programs”, further commented by Bob Zhang, CEO of KBI.

Elvert et al 2018 Team Players or opponents.pdf

Elvert-2018-Running on mixed fuel-dual agonist.pdf